Key Drivers
- Exceptional Margins
- Strong Liquidity
- Low Leverage
AIAI Summary
KRYS is a profitable, cash-rich VYJUVEK franchise—not a typical cash-burning biotech—but its premium valuation demands sustained U.S. growth, timely European launches, and validating pipeline data, making investors best served waiting for evidence of durable expansion rather than chasing recent strength.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Exceptional Margins
- •Strong Liquidity
- •Low Leverage
KRYS combines exceptional profitability, strong cash generation, ample liquidity, and minimal debt, but its elevated valuation and investment outflows warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Support Test
- •Weak Momentum
- •$350 Reclaim
KRYS is testing $336–$337 support amid weak momentum below its ~$350 average; a sustained move above $350 would improve the outlook, while a break below support signals further downside.
Fell about 9% from the $371 high over the last month
Sentiment & News
Key News Insights:
- •Vyjuvek Growth
- •Institutional Buying
- •Pipeline Expansion
Krystal Biotech's momentum is supported by Vyjuvek growth, pipeline expansion, and rising institutional ownership.
The developments are positive for investor sentiment and may support continued share-strength momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings